Clinical trial
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
NCT00456027 · Diamyd Therapeutics AB, Industry · Completed
Key facts
| NCT number | NCT00456027 |
|---|---|
| Title | Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult) |
| Official title | A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult) |
| Lead sponsor | Diamyd Therapeutics AB, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Latent Autoimmune Diabetes in Adult (LADA) |
| Intervention type | Drug |
| Interventions | rhGAD65 formulated in Alhydrogel® (Diamyd®) |
| Enrollment | 160 |
| Start date | Dec 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 4, 2007 |
| Last update posted | Jun 10, 2011 |
| Countries | Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: